GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

Size: px
Start display at page:

Download "GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:"

Transcription

1 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country. GSK Medicine: Camicinal, (040) Study Number: MOT Title: A randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the effect of repeat doses of 040 on the pharmacokinetics of L-DOPA in subjects with Parkinson s disease exhibiting delayed gastric emptying. Rationale: The main aim of this study was to determine if repeat administration of camicinal, through its ability to facilitate efficient gastric emptying, improves the absorption and pharmacokinetic profile of a given dose of L-DOPA resulting in improved Parkinson s symptom control as reflected by decreased OFF time and decreased Parkinson s disease motor symptoms. Phase: 2a Study Period: 06 Jul May 2014 Study Design: This was a repeat dose, multicentre, randomised, parallel-group, double-blind, placebo-controlled study. The study consisted of a screening period of up to 21 days, a 7-9 day treatment period, and a 14 day follow-up period. Centres: 11 Centres globally; 3 sites UK, 6 sites Germany, 1 site Sweden and 1 site Australia Indication: Camicinal is under investigation as an adjunctive treatment of motor symptom fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor therapy in adult patients with Parkinson's disease Treatment: Participants received placebo or camicinal 50 milligrams () (except for one participant who received camicinal 125 ) administered orally once daily for 7 to 9 days. Objectives: The primary objective of this study was to estimate the relationship between co-administration of camicinal on L-DOPA pharmacokinetic exposure in subjects with Parkinson s disease and slow or delayed gastric emptying. The secondary objectives were to measure the effect of camicinal on gastric emptying (GE); to determine the effect of camicinal on motor symptoms and amount of OFF time, to evaluate the safety and tolerability profile of co-administration of camicinal and L-DOPA; to evaluate the PK profile of camicinal Primary Outcome (Endpoints)/Efficacy : L-DOPA PK at screening (baseline), Days 1 and 8: dose-normalized AUC(0-4), dose-normalized Cmax, Tmax, t½ Secondary Outcome (Endpoints)/Efficacy : GE at screening (baseline), Days 1 and 8, as measured by the 13 C oral breath test (OBT (GE t½)) The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor and nonmotor score at screening (baseline), Days 1 and 8 Amount of awake time (in hours) spent ON, ON with troublesome dyskinesias, and OFF at screening (baseline), Days 1 through 8 Change in number of times subject can alternatively tap two (2) counter keys 30 cm apart in 1 minute during visit assessment (finger tapping). L-DOPA dose level and/or dosing frequency changes Vital signs, ECG, clinical laboratory data and adverse events Camicinal PK on Days 1 and 8: AUC, Cmax, tmax Statistical Methods: All safety analyses were performed on the All Subjects population which included all subjects who received at least one dose of study medication, i.e. placebo, camicinal 50 or camicinal 125. All pharmacodynamics, efficacy and pharmacokinetics analyses were performed on the Pharmacodynamic and Efficacy population which included all subjects who received at least one dose of placebo or camicinal 50. Prior to protocol amendment 4, one subject received camicinal 125. This subject was therefore excluded from all pharmacodynamics, efficacy and pharmacokinetics analyses. An estimation approach was used for all endpoints (except L-DOPA Tmax, which was analysed using a nonparametric method).confidence intervals were therefore calculated for the difference (or ratio) between camicinal 50 and placebo for each endpoint. Confidence intervals which do not contain 0 (or 1) indicate that the difference (or ratio) is statistically significant. The planned sample size of N=45 (N=30 for the camicinal 50 group, N=15 for the placebo group) was statistically powered (90% power, 5% alpha) to detect a 1.5 fold change in the mean AUC(0-4 hrs) (i.e. ratio of mean AUC(0-4 hrs) in camicinal 50 to mean AUC(0-4hrs) in placebo is 1.5). 1

2 Primary Outcome L-DOPA dose-normalised AUC(0-t) (t=0.5, 1.0, 1.5, 2.0, 2.5, , 4.0 hours) and Cmax: The nominal parameters values were normalised to the L-DOPA dose taken just prior to dosing. Following loge-transformation, the parameters were statistically analysed by a mixed model fitting treatment, visit and the interaction as fixed effects, and subject as a random effect grouped by treatment. Baseline measurements of L-DOPA PK parameters and gastric half emptying time (GE t1/2) were included as covariates. The ratio of geometric means of camicinal to placebo for Day 1 and Day 8 was derived from the model. A ratio > 1 indicates higher exposure in the camicinal 50 group compared to placebo. Tmax: the change from baseline was derived for Day 1 and Day 8 and analysed separately for each visit using a Wilcoxon Rank-sum test. T1/2: This endpoint was not assessed because there were insufficient L-DOPA data/profiles to calculate this parameter. Secondary outcomes Gastric emptying t1/2: The change from baseline in gastric half emptying time (GE t1/2) was analysed using a mixed model fitting treatment, visit, treatment*visit, baseline gastric emptying t1/2 as fixed effects, and subject as a random effect. The difference between camicinal 50 and placebo for Day 1 and Day 8 was estimated from the model. MDS-UPDRS: The change from baseline in each part of the MDS-UPDRS and total score at the pre-l-dopa dose time point was analysed using a mixed model fitting treatment, visit, treatment*visit, baseline score as fixed effects, and subject as a random effect. The difference between camicinal 50 and placebo for Day 1 and Day 8 was estimated from the model. The change from baseline in MDS-UPDRS part 3 was also derived for at each post-dose time point and analysed using a mixed model fitting treatment, visit, time point and the interaction as fixed effects, time point as repeated effect and subject as a random effect. The baseline measurement of MDS-UPDRS-3 score was included as a covariate in the model. The difference between camicinal 50 and placebo for each time point on Day 1 and Day 8 was estimated from the model. Amount of awake time (in hours) spent ON ON with troublesome dyskinesias, and OFF : The amount of awake hours spent in each state was averaged over a period of 48 hours during the screening period (to be used as baseline) and over days 6-7 of treatment (the treatment period). The change from baseline in the amount of hours spent in each state was analysed using an ANOCVA model, with treatment as a main effect and the baseline amount of hours as a covariate. The difference between camicinal 50 and placebo at the treatment period was estimated from the model. Finger tapping: The change from baseline in finger tap assessment was analysed by a mixed model fitting treatment, visit, time point and the interaction as fixed effects, time point as repeated effect and subject as a random effect. The baseline measurement of finger tap was included as a covariate in the model. The difference between camicinal 50 and placebo for each time point on Day 1 and Day 8 was estimated from the model. L-DOPA dose level and/or dosing frequency changes: The total daily L-DOPA equivalent dose was summarised by study day and treatment. Vital signs, ECG, clinical laboratory data and adverse events: All safety parameters were summarised descriptively. Camicinal PK: Individual camicinal concentration-time profiles for Day 1 and Day 8 were plotted and the concentrations were summarised by visit and time point. PK parameters were calculated from these concentration-time profiles using noncompartmental methods and summarised by visit. Study Population: Male or female subjects, aged years old, with advanced Parkinson disease taking L- DOPA with suboptimal motor control. Patients had to be receiving a stable dose of L-DOPA for at least 4 weeks prior to the screening visit and had to have a gastric emptying t ½ time of 70 mins as determined by the 13C-oral breath test. Patients with late stage advanced disease with incapacitating peak dose or biphasic dyskinesia on a stable L- DOPA regime and patients taking medications potentially influencing upper gastrointestinal motility or appetite within one week of the study (e.g., prokinetic drugs, macrolide antibiotics (erythromycin), GLP-1 mimetics) were excluded from the study. Number of Subjects: 040 Total 2

3 50, 125 Planned, N Randomised, N Dosed, N (in All Subjects population) Completed, n (% ) 18 (95) 37 (97) 55 (96) Total Number Subjects Withdrawn, N (%) 1 (5) 1 (3) 2(4) Withdrawn due to Adverse Events n (%) Withdrawn due to Lack of Efficacy n (%) Withdrawn for other reasons n (%) 1 (5) 1 (3) 2(4) Demographics Age (Years) Mean 66.7 (8.04) 67.4 (7.97) 67.1 (7.93) Sex, n (%) Females: 11 (58) 9 (24) 20 (35) Males: 8 (42) 29 (76) 37 (65) BMI (Kg/m 2 ), Mean (4.256) (3.434) (3.693) Height (cm), Mean (6.69) (6.75) (7.11) Weight (Kg), Mean (12.466) (11.118) (11.608) Ethnicity, n (%) Hispanic or Latino: Not Hispanic or Latino: 19 (100) 38 (100) 57 (100) White, n (%) 19 (100) 38 (100) 57 (100) Primary Efficacy Results: L-DOPA PK Parameter (units) AUC (0-0.5h) (ng.h/ml/) AUC (0-1h) (ng.h/ml/) AUC (0-1.5h) (ng.h/ml/) AUC (0-2h) (ng.h/ml/) Baseline Day 1 Day 8 n Geometric Mean (SD logs) 0.48 (1.816) 0.72 (1.255) 0.69 (1.483) 0.80 (1.361) 0.55 (0.820) 0.57 (1.443) (0.464, 2.095) (0.404, 1.874) n Geometric Mean (SD logs) 2.66 (1.321) 2.62 (1.186) 3.14 (1.143) 3.56 (0.951) 2.91 (0.814) 2.96 (0.881) (0.653, 1.861) (0.594, 1.727) n Geometric Mean (SD logs) 5.79 (1.094) 5.72 (0.918) 7.73 (0.672) 7.55 (0.662) 6.58 (0.770) 6.57 (0.635) (0.678, 1.369) (0.707, 1.452) n Geometric Mean (SD logs) 9.41 (0.906) 9.34 (0.707) (0.501) (0.510) (0.698) (0.489) (0.697, 1.214) (0.753, 1.328) AUC (0-2.5h) n

4 (ng.h/ml/) Geometric Mean (SD logs) (0.690) (0.526) (0.416) (0.407) (0..607) (0.416) (0.739, 1.176) (0.754, 1.211) AUC (0-3h) n (ng.h/ml/) Geometric Mean (SD logs) (0.525) (0.392) (0.379) (0.375) (0.503) (0.379) (0.799, 1.195) (0.740, 1.105) AUC (0-3.5h) n (ng.h/ml/) Geometric Mean (SD logs) (0.423) (0.354) (0.366) (0.364) (0.438) (0.358) (0.813, 1.144) (0.742, 1.045) AUC (0-4h) n (ng.h/ml/) Geometric Mean (SD logs) (0.363) (0.350) (0.365) (0.366) (0.406) (0.350) (0.831, 1.120) (0.763, 1.029) Cmax n (ng/ml/) Geometric Mean (SD logs) (0.275) (0.408) (0.317) (0.463) (0.364) (0.405) (0.702, 1.064) (0.824, 1.257) Tmax (h) n Median (range) (0.3- (0.3, ( ) (0.3, 3.5) (0.5, 3.5) (0.3, 4.0) 3.6) 4.0) Median change from baseline (range) 0.00 (- 2.3, 1.3) (- 3.5, 1.0) 0.47 (- 1.6, 1.8) 0.00 (- 2.8, 2.9) P-value T1/2 N/A Secondary Outcome Results: Half Gastric Emptying Time (t1/2) (mins) Baseline Day 1 Day n Mean 99.6 (21.26) 96.9 (21.67) 97.5 (15.81) 91.9 (21.47) 98.7 (25.03) 90.6 (26.75) -2.1 (25.37) -5.0 (17.76) -0.4 (25.90) -4.4 (26.17) Adjusted Means Change ( , 7.537) ( , 6.914) Pre-L-DOPA Dose MDS-UPDRS 4

5 MDS-UPDRS Part Baseline Day 1 Day Part 1 n Mean 9.1 (4.56) 10.1 (6.17) 10.1 (4.98) 8.6 (5.12) 10.0 (5.25) 7.1 (4.67) Baseline 1.0 (2.98) -1.5 (2.93) 1.1 (4.65) -3.0 (3.87) Adjusted (-3.90, -0.41) (-5.41, -1.85) Part 2 n Mean 14.9 (7.09) 12.5 (6.33) 16.1 (9.09) 11.5 (6.54) 15.3 (9.29) 10.3 (6.37) Baseline 1.2 (4.16) -1.0 (3.00) 0.6 (5.04) -1.7 (4.60) Adjusted (-4.65, 0.07) (-4.85, -0.07) Part 3 n Mean 42.2 (14.63) 38.0 (18.95) 40.4 (17.56) 34.9 (17.97) 44.2 (19.25) 34.0 (17.46) Baseline -1.8 (6.33) -3.1 (8.96) 1.5 (8.64) -3.9 (9.11) Adjusted (-6.53, 3.13) (-10.28, -0.49) Part 4 n Mean 5.5 (2.70) 5.3 (3.63) 5.9 (3.07) 5.2 (3.61) 5.7 (3.79) 4.5 (3.41) Baseline 0.4 (1.84) -0.1 (1.98) 0.2 (2.71) -0.7 (1.66) Adjusted (-1.65, 0.54) (-2.02, 0.22) Total Score n Mean 71.7 (23.53) 65.8 (27.02) 72.5 (29.01) 60.2 (25.90) 75.2 (34.27) 55.9 (25.34) Baseline 0.8 (10.20) -5.7 (10.34) 3.3 (18.32) -9.2 (12.13) Adjusted (-13.77, 0.39) (-19.67, -5.29) MDS-UPDRS Part 3 Time point Baseline Day 1 Day mins n Mean (16.61) (16.04) (15.01) (16.25) (14.90) 24.2 (14.24) 5

6 -0.8 (6.81) -1.5 (7.03) -0.9 (10.49) -2.8 (8.42) (-9.11, 2.75) (-9.96, 2.03) 180 mins n Mean 30.3 (14.55) 27.5 (14.21) 31.0 (17.10) 25.5 (18.04) 33.3 (16.17) 25.1 (14.27) 0.7 (10.41) -1.5 (10.22) 3.1 (9.76) -1.2 (8.55) (-9.59, 2.27) (-11.29, 0.71) 240 mins n Mean 31.6 (16.27) 29.2 (16.62) 32.7 (20.50) 27.2 (17.68) 37.1 (20.19) 25.4 (15.27) 1.1 (12.36) -1.9 (8.77) 5.1 (11.58) -2.8 (8.16) (-10.07, 1.76) (-14.88, -2.91) ON/OFF symptoms Amount of hours spent ON Amount of hours spent OFF Baseline (Day -2 and -1) Treatment (Day 6 and 7) n Mean (3.602) (3.021) (3.927) (3.375) (2.922) 1.03 (2.786) 1.88 (0.28, 3.48) n Mean 4.92 (3.417) 4.23 (2.484) 5.57 (4.364) 2.94 (2.954) 0.93 (2.629) (2.236) (-3.71, -0.90) Finger Tapping (taps per min) Pre-L- DOPA Dose Baseline Day 1 Day n Mean (47.53) (38.00) (43.44) (40.05) (40.90) (43.92) -0.1 (11.65) 7.3 (15.23) 3.1 (14.50) 13.5 (17.65) 6

7 -2.83 (-21.79, 16.13) 0.51 (-18.51, 19.52) 0 min n Mean 91.2 (49.84) 80.1 (35.28) 90.7 (40.78) 86.8 (44.65) 92.0 (44.30) 91.1 (42.90) -0.5 (20.04) 8.3 (16.97) 0.3 (21.31) 11.6 (13.96) 0.58 (-18.39, 19.56) 3.32 (-15.70, 22.33) 30 min n Mean 89.3 (42.91) 85.2 (41.45) 93.4 (43.95) 92.4 (49.92) 95.8 (45.07) 92.2 (41.14) 3.2 (12.61) 8.3 (10.98) 6.3 (16.90) 6.1 (10.27) 1.84 (-17.18, 20.86) (-21.97, 16.08) 60 min n Mean 88.6 (42.32) 89.3 (45.32) 93.8 (44.80) 94.6 (44.06) 94.6 (46.80) 93.2 (39.01) 4.9 (12.66) 3.5 (19.00) 5.5 (11.63) 0.8 (21.75) 0.28 (-18.72, 19.28) (-22.13, 15.88) 90 min n Mean 91.2 (44.14) 90.8 (45.18) 97.7 (50.46) 91.4 (42.09) 95.0 (48.82) 95.5 (42.60) 6.6 (16.72) 2.9 (18.37) 3.3 (14.43) 1.7 (21.46) (-22.35, 15.58) (-20.40, 17.63) 120 min n Mean 92.6 (40.99) 92.0 (43.37) 99.9 (50.51) 96.4 (42.06) 97.2 (47.67) 97.4 (42.34) 7.3 (17.46) 3.5 (15.67) 4.3 (13.30) 3.5 (14.45) (-23.13, 14.76) (-19.70, 18.28) 180 min n Mean 94.1 (47.19) 92.8 (44.86) 99.0 (49.44) 92.3 (41.01) 96.8 (52.50) (49.86) 4.9 (15.90) -0.5 (15.82) 2.6 (13.07) 6.0 (21.73) (-25.36, 12.58) 3.02 (-15.98, 22.02) 240 min n Mean 95.2 (44.60) 93.2 (46.17) 98.2 (51.97) 97.6 (48.40) 98.3 (53.30) (51.84) 2.1 (16.68) 4.3 (15.19) 2.6 (16.42) 7.7 (23.12) 7

8 0.77 (-18.20, 19.75) 4.08 (-14.91, 23.07) Total daily L-DOPA equivalent dose () Study Day Baseline n Mean (41.14) (119.66) Day 1 n Mean (174.85) (216.54) Day 2 n Mean (229.61) (300.44) Day 3 n Mean (243.79) (299.98) Day 4 n Mean (241.50) (313.07) Day 5 n Mean (243.13) (293.48) Day 6 n Mean (249.21) (307.31) Day 7 n Mean (247.51) (310.57) Day 8 n Mean (175.43) (234.00) 040 PK PK Parameter (Units) Day 1 Day 8 AUC(0-5.5) n (ng.h/ml) Geometric Mean (SD logs) (0.368) (0.437) Cmax (ng/ml) n Geometric Mean (SD logs) (0.433) (0.438) Tmax (h) n Mean (0.9660) (0.9863) Safety Results: An on therapy adverse event (AE) was defined as an AE with onset on or after the start date of study medication., 125 (N=38) Most Frequent Adverse Events On-Therapy n (%) n (%) Subjects with any AE(s), n(%) 17 (89%) 24 (63%) Headache 7 (37%) 9 (24%) Fatigue 2 (11%) 5 (13%) Nausea 4 (21%) 3 (8%) Constipation 3 (16%) 2 (5%) Dizziness 4 (21%) 1 (3%) Abdominal pain upper 2 (11%) 2 (5%) Back pain 1 (5%) 3 (8%) Diarrhoea 2 (11%) 1 (3%) Muscle spasms 3 (16%) 0 8

9 Toothache 2 (11%) 1 (3%) Anaemia 2 (11%) 0 Arthralgia 2 (11%) 0 Dyskinesia 0 2 (5%) Parkinson's disease 2 (11%) 0 Pruritus 0 2 (5%) Somnolence 0 2 (5%) Serious Adverse Events - On-Therapy n (%) [n considered by the investigator to be related to study medication], 125 (N=38) Subjects with non-fatal SAEs, n (%) 2 (11%) 2 (5%) n (%) [related] n (%) [related] 1 (5%) [0] 0 Ankle fracture Rib fracture 1 (5%) [0] 0 Parkinson's disease 1 (5%) [1] 0 Pruritus 0 1 (3%) [0] Circulatory collapse 0 1 (3%) [0] Subjects with fatal SAEs, n (%) 0 0 Conclusion: There were no significant differences in the L-DOPA exposure (as assessed by AUC) after the initial dose or after 8 days dosing of placebo or camicinal 50. Nonetheless, the group receiving camicinal had statistically and clinically meaningful less OFF time and more ON time than those receiving placebo. In addition, there was a statistically and clinically meaningful improvement in symptoms related to motor dysfunction in subjects receiving camicinal verses those receiving placebo. This improvement in OFF time may be related to an associated decrease (30-60 minutes) in the time to maximal L-DOPA plasma concentration (Tmax) observed in this study. There was a moderate, nonsignificant improvement in half gastric emptying time compared to placebo. No differences were observed between camicinal and placebo in the number of finger taps per minute or in the L-DOPA dosage. In the camicinal treatment group, a total of 24 (63%) subjects reported non-serious adverse events, with the most frequent events being headache, fatigue, back pain and nausea. In the placebo treatment group, 17 (89%) subjects reported non-serious adverse events, with the most frequent being headache, nausea and dizziness. Non-fatal serious adverse events of pruritus and circulatory collapse were reported in the camicinal treatment group and rib fracture, ankle fracture and Parkinson s disease (worsening) in the placebo treatment group. There were no fatalities reported in this study. 9

Japanese, Korean and Chinese subjects had also lived outside their respective countries for less than 10 years.

Japanese, Korean and Chinese subjects had also lived outside their respective countries for less than 10 years. The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study Centers: This study was conducted in 2 centers in Italy.

Study Centers: This study was conducted in 2 centers in Italy. Title of Trial: A randomised, double-blind, placebo-controlled, two-period, two-sequence-crossover interaction study to assess the effect of safinamide on levodopa pharmacokinetics in subjects with Parkinson

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Treatment A Placebo to match COREG CR 20 mg OD + Lisinopril 10 mg OD (Days 1-7) Placebo to match COREG CR 40 mg OD + Lisinopril 10 mg OD (Days 8-14)

Treatment A Placebo to match COREG CR 20 mg OD + Lisinopril 10 mg OD (Days 1-7) Placebo to match COREG CR 40 mg OD + Lisinopril 10 mg OD (Days 8-14) The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No: Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Statistical Methods:

Study No: Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Statistical Methods: Study No: MNK111587 Title : A healthy volunteer repeat dose study to evaluate; the safety, tolerability, pharmacokinetics, effects on the pharmacokinetics of midazolam and the neurokinin-1 (NK1) receptor

More information

HM2008/00566/00. study and to obtain clinical experience with the use of this drug. Primary Outcome/Efficacy Variable(s): <Pharmacokinetics>

HM2008/00566/00. study and to obtain clinical experience with the use of this drug. Primary Outcome/Efficacy Variable(s): <Pharmacokinetics> The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Study Endpoints: Pharmacokinetics:

Study No Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Study Endpoints: Pharmacokinetics: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

SYNOPSIS. Study centre(s) The study was performed in Denmark, Norway and Sweden at 20 sites.

SYNOPSIS. Study centre(s) The study was performed in Denmark, Norway and Sweden at 20 sites. Drug substance(s): AZD0837 Edition No.: 1 Study code: D1250C00007 Date: 22 May, 2006 SYNOPSIS (For national authority use only) A Controlled, Randomised, Parallel, Multicentre Study to Assess Safety and

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable: Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Subjects from the Safety Population who had GSK PK parameter estimates from any portion of the study. Cohort 1 (N=8)

Subjects from the Safety Population who had GSK PK parameter estimates from any portion of the study. Cohort 1 (N=8) The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

mg 25 mg mg 25 mg mg 100 mg 1

mg 25 mg mg 25 mg mg 100 mg 1 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Sponsor Novartis. Generic Drug Name. NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia

Sponsor Novartis. Generic Drug Name. NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia Page 1 Sponsor Novartis Generic Drug Name NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia Approved Indication Investigational. Study Number CA2206 Title A

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Treatment B: FF (400 µg) and UMEC (250 µg)/vi(100 µg) The indicated dose is the total of four inhalations via the dry powder inhaler.

Treatment B: FF (400 µg) and UMEC (250 µg)/vi(100 µg) The indicated dose is the total of four inhalations via the dry powder inhaler. GSK Medicine:GSK573719 (Umeclidinium)+ GW6424 (Vilanterol) + GW685698 (Fluticasone furoate) Study Number: 200587 Title: An open label, randomised, four-period crossover, single dose study in healthy volunteers

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable: Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study Population: 12 years and older A EF Calcipotriene Foam, 0.005%

Study Population: 12 years and older A EF Calcipotriene Foam, 0.005% Study No.: CAL.203 Title: A Randomized, Open-Label Study to Assess the Bioavailability of Emulsion Formulation Foam, 0.005%, and Dovonex, 0.005%, in Patients with Mild to Moderate Plaque-Type Psoriasis

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

Study No: Title: Rationale: . Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No: Title: Rationale: . Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives:

Study No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable(s):

Study No Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable(s): Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No: Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Statistical Methods: Sample Size

Study No: Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Statistical Methods: Sample Size The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

This was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study.

This was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study. The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Sponsor Novartis. Generic Drug Name AFQ056. Therapeutic Area of Trial L-dopa induced dyskinesias in Parkinson s disease (PD-LID)

Sponsor Novartis. Generic Drug Name AFQ056. Therapeutic Area of Trial L-dopa induced dyskinesias in Parkinson s disease (PD-LID) Sponsor Novartis Generic Drug Name AFQ056 Therapeutic Area of Trial L-dopa induced dyskinesias in Parkinson s disease (PD-LID) Approved Indication Investigational Protocol Number CAFQ056A2223 Title 13-week,

More information

Study No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: ADF Title: Phase III study of adefovir dipivoxil (ADV) tablets in patients with compensated chronic hepatitis B -comparative study

Study No.: ADF Title: Phase III study of adefovir dipivoxil (ADV) tablets in patients with compensated chronic hepatitis B -comparative study Study No.: ADF105220 Title: Phase III study of adefovir dipivoxil () tablets in patients with compensated chronic hepatitis B -comparative study against lamivudine ()- Rationale: This study wass a confirmatory

More information

UMEC/VI vs. UMEC in subjects who responded to UMEC UMEC/VI vs. VI in subjects who responded to VI

UMEC/VI vs. UMEC in subjects who responded to UMEC UMEC/VI vs. VI in subjects who responded to VI The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:

Study No Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Hydrocodone/Acetaminophen Extended-Release Tablets M Clinical Study Report R&D/09/1109

Hydrocodone/Acetaminophen Extended-Release Tablets M Clinical Study Report R&D/09/1109 2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-712 Volume: Hydrocodone/Acetaminophen Extended-Release Name

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number:

GSK Medicine: Study Number: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Study No.: 29060/717 Title: A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of CR Intermittent Dosing (12.5 mg and 25 mg) for Premenstrual Dysphoric Disorder Rationale: In most trials investigating

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Clinical Trial Results Database Page 1

Clinical Trial Results Database Page 1 Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Therapeutic Area of Trial L-dopa induced dyskinesias in Parkinson s disease (PD-LID) Approved Indication Not approved yet for any

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

SYNOPSIS. Co-ordinating investigator Not applicable. Study centre(s) This study was conducted in Japan (57 centres).

SYNOPSIS. Co-ordinating investigator Not applicable. Study centre(s) This study was conducted in Japan (57 centres). Drug product: Symbicort Turbuhaler Drug substance(s): ST (Symbicort Turbuhaler ) Edition No.: 1.0 Study code: D5890C00010 Date: 15 March 2007 SYNOPSIS An 8-week, randomised, double blind, parallel-group,

More information

BRL /RSD-101C0D/1/CPMS-704. Report Synopsis

BRL /RSD-101C0D/1/CPMS-704. Report Synopsis Report Synopsis Study Title: A Randomized, Multicenter, 10-Week, Double-Blind, Placebo- Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Sponsor: Sanofi Drug substance(s): SAR342434

Sponsor: Sanofi Drug substance(s): SAR342434 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Study Day 1 Study Days 2 to 9 Sequence 1 Placebo for moxifloxacin Study Days 2 to 8: placebo for pazopanib (placebopaz) 800 mg;

Study Day 1 Study Days 2 to 9 Sequence 1 Placebo for moxifloxacin Study Days 2 to 8: placebo for pazopanib (placebopaz) 800 mg; The study listed may include approved non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Secondary Outcome/Efficacy Variable(s):

Secondary Outcome/Efficacy Variable(s): The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of

More information

Sponsor / Company: Sanofi Drug substance: SAR236553/REGN727 (alirocumab)

Sponsor / Company: Sanofi Drug substance: SAR236553/REGN727 (alirocumab) These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance:

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Mipomersen (ISIS ) Page 2 of 1979 Clinical Study Report ISIS CS3

Mipomersen (ISIS ) Page 2 of 1979 Clinical Study Report ISIS CS3 (ISIS 301012) Page 2 of 1979 2 SYNOPSIS ISIS 301012-CS3 synopsis Page 1 Title of Study: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics,

More information

(For National Authority Use Only) Name of Study Drug: to Part of Dossier:

(For National Authority Use Only) Name of Study Drug: to Part of Dossier: 2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Vicodin CR Name of Active Ingredient: Page: Hydrocodone/Acetaminophen

More information

GSK Medicine Study Number: Title: Rationale Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine Study Number: Title: Rationale Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and nonapproved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. SYNOPSIS Issue Date: 27 April 2009 Document No.: EDMS-PSDB-9908562:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient Johnson & Johnson Pharmaceutical Research & Development,

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Principal Investigator: Marion, Alan, S, M.D., MDS Pharma Services (US) Inc., 621 Rose Street, PO Box 80837, Lincoln, NE 68502, USA

Principal Investigator: Marion, Alan, S, M.D., MDS Pharma Services (US) Inc., 621 Rose Street, PO Box 80837, Lincoln, NE 68502, USA SYNOPSIS Issue Date: 06 October 2008 Document No.: EDMS-PSDB-8954363:2. Name of Sponsor/Company Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Name of Finished Product Name of Active Ingredient(s)

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

SYNOPSIS OF RESEARCH REPORT (PROTOCOL BC20779)

SYNOPSIS OF RESEARCH REPORT (PROTOCOL BC20779) TITLE OF THE STUDY / REPORT No. / DATE OF REPORT INVESTIGATORS / CENTERS AND COUNTRIES Clinical Study Report Protocol BC20779: Multicenter, double-blind, randomized, placebo-controlled, dose ranging phase

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Study No: LOV OMA-104 Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Statistical Methods

Study No: LOV OMA-104 Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Statistical Methods The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

PFIZER INC. Study Initiation Date and Completion Dates: 09 March 2000 to 09 August 2001.

PFIZER INC. Study Initiation Date and Completion Dates: 09 March 2000 to 09 August 2001. PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of

More information

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI) PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.

PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. Public Disclosure Synopsis Protocol A7772 September 25 Final PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

SYNOPSIS. International co-ordinating investigator Redacted

SYNOPSIS. International co-ordinating investigator Redacted Drug product: Drug substance(s): AZD6140 Document No.: D5130C00002 Edition No.: 01 Study code: D5130C00002 Date: 12 October 2005 SYNOPSIS A Double-blind, Double-dummy, Parallel Group Randomised Dose Confirmation

More information

Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Secondary Outcome/Efficacy Variable(s): Statistical Methods:

Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Secondary Outcome/Efficacy Variable(s): Statistical Methods: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Sponsor: Sanofi Drug substance(s): GZ316455

Sponsor: Sanofi Drug substance(s): GZ316455 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):

More information

Referring to Part IV of the Dossier

Referring to Part IV of the Dossier 2. SYNOPSIS Name of Company: Mundipharma Research Limited Name of Finished Product: FlutiForm Name of Active Ingredient: Fluticasone propionate / Formoterol fumarate INDIVIDUAL STUDY TABLE Referring to

More information

Individual Study Table Referring to Part of Dossier: Volume: Page:

Individual Study Table Referring to Part of Dossier: Volume: Page: Synopsis Abbott Laboratories Name of Study Drug: DUODOPA Intestinal Gel Name of Active Ingredient: Levodopa-carbidopa Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information